Rigel Pharmaceuticals, Inc. (RIGL) — Financial statements
Income statement, balance sheet, and cash flow for Rigel Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 294↑64.1% | 179↑53.4% | 117↓2.8% | 120↓19.4% | 149 | |
| Cost of Revenue | 20↑5.2% | 19↑162.3% | 7↑306.5% | 2↑61.5% | 1 | |
| Gross Profit | 275↑71.0% | 161↑46.3% | 110↓7.4% | 118↓20.0% | 148 | |
| Operating Expenses | ||||||
| R&D Expenses | 33↑42.4% | 23↓4.7% | 25↓59.3% | 60↓7.6% | 65 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 116↑2.5% | 113↑6.9% | 106↓6.0% | 112↑22.4% | 92 | |
| Other Expenses | 0.00 | 0.00 | 0.00↓100.0% | 1↓62.5% | 4 | |
| Operating Expenses | 149↑9.3% | 136↑4.7% | 130↓25.2% | 174↑8.3% | 161 | |
| Total Costs & Expenses | 169↑8.9% | 155↑12.9% | 137↓21.9% | 176↑8.7% | 162 | |
| Operating Results | ||||||
| Operating Income | 125↑418.6% | 24↑218.1% | -20↑63.1% | -56↓344.5% | -12 | |
| Depreciation & Amortization | 2↑8.4% | 2↑80.0% | 1↑24.0% | 1.00↓14.1% | 1 | |
| EBITDA | 132↑361.4% | 29↑267.9% | -17↑68.5% | -54↓377.3% | -11 | |
| EBIT | 129↑391.4% | 26↑244.3% | -18↑66.8% | -55↓340.7% | -12 | |
| Interest & Other Income | ||||||
| Net Interest Income | -4↑37.5% | -6↓26.7% | -5↓52.2% | -3↑37.2% | -5 | |
| Interest Income | 4↑76.0% | 2↓7.9% | 2↑232.2% | 0.68↑1355.3% | 0.05 | |
| Interest Expense | 7↓7.6% | 8↑15.2% | 7↑85.4% | 4↓23.7% | 5 | |
| Non-Operating Income | -4↓76.0% | -2↑7.9% | -2↓232.2% | -0.68↓1355.3% | -0.05 | |
| Other Income / Expenses | -4↑37.5% | -6↓26.7% | -5↓52.2% | -3↑37.2% | -5 | |
| Income Before Tax | 122↑563.3% | 18↑173.2% | -25↑57.2% | -59↓238.4% | -17 | |
| Income Tax Expense | -245↓27931.7% | 0.88 | 0.00 | 0.00↓100.0% | 0.61 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 367↑1999.1% | 17↑169.7% | -25↑57.2% | -59↓227.0% | -18 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 367↑1999.1% | 17↑169.7% | -25↑57.2% | -59↓227.0% | -18 | |
| Bottom-Line Net Income | 367↑1999.1% | 17↑169.7% | -25↑57.2% | -59↓227.0% | -18 | |
| EPS (Basic) | 20.40↑1960.6% | 0.99↑168.7% | -1.44↑57.6% | -3.40↓209.1% | -1.10 | |
| EPS (Diluted) | 19.48↑1867.7% | 0.99↑168.7% | -1.44↑57.6% | -3.40↓209.1% | -1.10 | |
| Weighted Average Shares | 18↑2.3% | 18↑1.0% | 17↑0.9% | 17↑1.1% | 17 | |
| Weighted Average Diluted Shares | 19↑6.5% | 18↑1.6% | 17↑0.9% | 17↑1.1% | 17 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.